Option Investor
Newsletter

NEW ADDITIONS TO THE MARCH RECOMMENDED LIST

HAVING TROUBLE PRINTING?
Printer friendly version

FOUR (4) additional positions being added to our MARCH RECOMMENDED LIST:

We are adding the following four (4) put writes to our MARCH RECOMMENDED LIST

We are recommending puts writes on the following issues:


ILSE - IntraLase Corp.
engages in the design, development, and manufacture of ultra-fast laser, related software, and disposable devices used to create a corneal flap, the first step in LASIK surgery for the correction of vision. The company"s products improve the safety, precision, and visual results of LASIK procedures by providing a computer-controlled laser solution in place of the hand-held mechanical, metal-bladed, microkeratome used to create corneal flaps. IntraLase lasers are also used in surgical approaches to the treatment of diseased corneas.

MCRI - Monarch Casino & Resort, Inc.
through its wholly owned subsidiary, Golden Road Motor Inn, Inc., engages in the ownership and operation of the Atlantis Casino Resort (ACR), a hotel/casino facility in Reno, Nevada. As of December 31, 2004, ACR features approximately 51,000 square-feet of casino space with 1,450 slot and video poker machines and 38 table games; a hotel and a motor lodge with rooms totaling 980; a sky terrace bridge; 7 restaurants; 7 bars; a nightclub; swimming pools; a health club and salon; a gift shop; a family entertainment center; a banquet and meeting space; and surface parking spaces for approximately 2,000 vehicles. The company was founded in 1972 and is based in Reno, Nevada.

MNTA - Momenta Pharmaceuticals, Inc.
engages in structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. The company's products include M-Enoxaparin, a technology-enabled generic version of Lovenox and a low molecular weight heparin(LMWH), which is used to prevent and treat deep vein thrombosis and treat acute coronary syndromes; M-Dalteparin, also a technology-enabled generic version of the LMWH Fragmin. It also offers Glycoproteins, M118, pulmonary delivery of proteins, and sugar therapeutic, which are in preclinical stages.

BCRX - BioCryst Pharmaceuticals, Inc.
engages in the design, optimization, and development of small-molecule drugs that treat cancer, cardiovascular, and autoimmune diseases, as well as viral infections. The company focuses on building potent, selective inhibitors of enzymes associated with targeted diseases. BioCryst Pharmaceuticals integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals. Its lead product candidate, Fodosine, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is in a Phase IIa trial for patients with T-cell leukemia and in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma.


We are recommending the following four (4) specific put writes:

ILSE 19.48
SELL ILSE MAR SYM: USL-OW
Target Price $25.00 17.5 Put
Potential Profit(10 x = $250.00
Initial Margin $4,146 10 (contracts)
Return on Investment 6.03%
Cost Basis in Stock = $17.25
Days to Expiration = 28
Stock goes on Watch List Price at: $19.50
STOP EXIT STRATEGY
Close option position if Stock CLOSES less than = >$17.50

MCRI $28.09
SELL MCRI MAR SYM: QIK-OE
Target Price $35.00 25 Put
Potential Profit(10 x = $350.00
Initial Margin $5,968 10 (contracts)
Return on Investment 5.86%
Cost Basis in Stock = $24.65
Days to Expiration = 28
Stock goes on Watch List Price at: $27.00
STOP EXIT STRATEGY
Close option position if Stock CLOSES less than = >$25.00


MNTA $25.05
SELL MNTA MAR SYM: QMP-OD
Target Price $30.00 20 Put
Potential Profit(10 x = $300.00

Initial Margin $5,310 10 (contracts)
Return on Investment 5.65%
Cost Basis in Stock = $19.70
Days to Expiration = 28
Stock goes on Watch List Price at: $22.00
STOP EXIT STRATEGY
Close option position if Stock CLOSES less than => $20.00


BCRX 19.07
SELL BCRX MAR SYM: BIU-OC
Target Price $25.00 15 Put
Potential Profit(10 x = $250.00

Initial Margin $4,064 10 (contracts)
Return on Investment 6.15%
Cost Basis in Stock = $14.75
Days to Expiration = 28
Stock goes on Watch List Price at: $17.00
STOP EXIT STRATEGY
Close option position if Stock CLOSES less than = > $15.00

When this positions are filled this will bring our MARCH RECOMMENDATION LIST
to EIGHT (8) positions


Option Writers Newsletter Archives